Table 2

Serum HER2 and YKL-40 concentrations and disease characteristic

Disease characteristicNo. involvedSerum HER2 (μg/liter) (median and range)Serum YKL-40 (μg/liter) (median and range)
InvolvedNot involvedPOR (95% CI) (P)aInvolvedNot involvedPOR (95% CI) (P)a
Lymph node involvement at primary diagnosis6012 (6–740)12 (6–1610)139 (38–1696)133 (28–552)
Receptor negative at primary diagnosis299 (6–740)12 (6–1610)138 (58–832)136 (28–1696)
Parenchymal involvement (outside lymph nodes and skin only)6415 (6–1610)9.5 (6–31)0.000066.2 (2.0–20) (0.001)157 (38–1696)109 (28–552)0.000513 (2.9–60) (0.0001)
Bone metastases (+ marrow = 11) without liver or lung metastases3314 (6–60)11 (6–1610)140 (44–688)134 (28–1696)
Lung metastases without liver metastases1311 (6–85)12 (6–1610)138 (38–1696)136 (28–832)
Liver metastases1844 (9–1610)11 (6–85)0.000018.6 (2.7–27) (0.0001)230 (96–832)126 (28–1696)0.0000514 (4.2–50) (0.00001)
More than two different metastatic sites1326 (6–740)11 (6–1610)0.03200 (69–832)130 (28–1696)0.0084.7 (1.4–16) (0.008)
Symptomatic disease (PS 1+ 2)2315 (8–1610)11 (6–900)0.006168 (72–832)118 (28–1696)0.0012.8 (1.1–7.4) (0.034)
Complete remission not induced6114 (6–1610)10 (6–40)0.0064.0 (1.5–11) (0.005)146 (38–832)118 (28–1696)0.062.8 (1.1–7.3) (0.036)
  • a High vs low level.